CONTRACT RESEARCH & TOXICOLOGY
Extreme potency, extreme precautions
The containment measures required for ADC handling are largely guided by Occupational Exposure Limits( OELs), which define the maximum concentration of a substance to which a worker may be exposed for eight hours a day and 40 hours per week without adverse health effects. OELs serve as critical indicators of hazard and form the basis for implementing appropriate risk management and exposure control strategies.
In cases where compound-specific OELs are unavailable, occupational exposure banding( OEB) can be used to support health-based risk management decisions. OEB classifies compounds into exposure bands according to their toxicological potency and associated health risks, with each band corresponding to a range of exposure concentrations considered safe for workers( Figure 2).
ADC payloads are among the most potent compounds handled in pharmaceutical laboratories( Table 1), often presenting OELs below 50 ng / m 3, 20 times lower than the 1 µ g / m 3 threshold of the highest toxicity category. Such concentration is comparable to dispersing only two grains of table salt in an Olympicsized swimming pool.
Figure 2 – OEL & OEB thresholds
OEB
5 |
< |
Extremely toxic |
|
1 µ g / m 3 |
|
Very toxic
3 10-100 µ g / m 3 Toxic
2 100- 1,000 µ glm 3 Mildly toxic
1 1,000-5,000 µ g / m 3
OEL
Consequently, laboratories handling ADC payloads must implement exceptionally stringent containment and safety measures to protect personnel and prevent cross-contamination. Safe operation depends on the integration of advanced facility engineering, rigorous operational controls, specialised personal protective equipment( PPE), continuous environmental monitoring and highly trained personnel.
The physical structure of the facility must be heavily focused on containment. High-potency suites must be segregated from other laboratory and office areas and designed with smooth, easily decontaminated surfaces, such as stainless steel and seamless epoxy flooring, to minimise residue accumulation.
HPAPIs must be handled inside enclosed systems, such as gloveboxes and isolators, rather than on open laboratory benches. Ventilation systems are designed for single-pass airflow, with exhaust air passing through high-efficiency particulate air( HEPA) filtration prior to release. In addition, containment rooms are maintained under negative pressure to prevent the escape of contaminants.
Non-toxic
Toxicity level
Personnel working with these compounds must follow strict gowning and de-gowning procedures and typically wear multiple layers of PPE, including disposable gowns, double gloves, sleeve covers and respiratory protection such as powered air-purifying respirators( PAPRs) or full-face respirators. Comprehensive training is also essential and generally includes toxicology awareness, contamination control, spill response, respirator use and proper containment practices.
Continuous monitoring is another critical aspect of operating these laboratories safely. Air sampling and surface wipe testing are routinely performed to confirm that containment systems are functioning properly and that worker exposure remains below OELs.
Although not mandatory, adherence to recognised containment and occupational safety standards is encouraged. These include the ISPE Good Practice Guide for containment performance testing, ASTM standards for airborne particulate containment measurement, ISO 45001 for occupational health and safety management systems and ISO 14001 for environmental management systems. Third-party certifications from organisations such as SafeBridge, which specialises in occupational safety assessments for HPAPI handling, are also widely regarded as indicators of robust containment and safety programmes.
Financial & operational burden
Building and operating a facility capable of safely handling ADC payloads is both technically complex and financially demanding. The infrastructure and operational controls required to manage some of the most hazardous compounds in the pharmaceutical industry involve substantial upfront investment and ongoing maintenance costs.
Establishing a dedicated HPAPI laboratory with appropriate containment systems typically
JUL / AUG 2026 SPECCHEMONLINE. COM
33